This site is intended for health professionals only
Wednesday 12 December 2018
Share |

Topic: cancer

November 29, 2018
First child cancer patients treated with new CAR-T therapy in UK

Children with cancer at Great Ormond Street Hospital in London are this week starting a new therapy treatment tailored to target patients’ specific cancer cells.
 
The CAR-T treatment involves collecting and using a patient’s own immune cells to fight the cancer over a number of weeks. 
 
Royal Manchester Children’s Hospital is also offering the immunotherapy treatment, and Newcastle upon Tyne Hospitals NHS Foundation Trust will join next month.
 

August 30, 2018
The European Commission has approved Vyxeos 44 mg/100mg powder for concentrate for solution for infusion for the treatment of adults with newly-diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes, manufacturer Jazz Pharmaceuticals has announced.

The European Commission has approved Vyxeos 44 mg/100mg powder for concentrate for solution for infusion for the treatment of adults with newly-diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes, manufacturer Jazz Pharmaceuticals has announced.
 
Vyxeos is an advanced liposomal formulation that delivers a synergistic molar ration of daunorubicin and cytarabine, Jazz Pharmaceuticals said.
 
The EC approval extends to all European member states as well as Iceland, Norway sand Liechtenstein.

August 30, 2018
Novartis UK Oncology statement on Novartis receiving European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel)

Novartis UK Oncology statement on Novartis receiving European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel)
 
"Today’s (27 August) approval by the European Commission of Kymriah® (tisagenlecleucel), the only CAR-T therapy licensed in two different types of blood cancers, moves us one step closer to providing this revolutionary therapy to appropriate patients in the UK. 
 
 
 

August 6, 2018
New patient groups with cancer-associated venous thromboembolism (VTE) could benefit from taking once-daily oral LIXIANA (edoxaban), a recent analysis has said.

New patient groups with cancer-associated venous thromboembolism (VTE) could benefit from taking once-daily oral LIXIANA (edoxaban), a recent analysis has said.
 
Manufacturer Daiichi Sankyo announced today (6 July) it had published a new analysis on the clinical presentation, course and outcome of bleeding events in Thrombosis and Haemostasis, and the associated tumour types from the Hokusai-VTE cancer study.
 

July 26, 2018
Steve Wiliams explains why he loves working in the field of cancer care

Working with cancer patients can be tough at times as despite all the effective new treatments, many patients still have incurable diseases. But being an oncology pharmacist is an amazing job and I would not swap it for anything else. 
 

July 2, 2018
The CHMP has given a positive opinion recommending Novartis’s Kymriah (tisagenlecleucel) to treat two aggressive blood cancers.

The Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion recommending Novartis’s Kymriah (tisagenlecleucel) to treat two aggressive blood cancers.
 
The CHMP, which is part of the European Medicines Agency (EMA), gave a positive opinion on using tisagenlecleucel to treat B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-stem cell transplant or in second or later relapse in patients up to 25 years of age.
 

June 21, 2018
Targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint inhibitors

A targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint inhibitors, researchers have found.
 
EZH2 is elevated in immune T cells in patients after treatment with ipilimumab, a team at the University of Texas MD Anderson Cancer Center showed. The drug unleashes an immune response by blocking the activity of CTLA-4 on T cells – white blood cells that serve as the ‘targeted warriors’ of the adaptive immune system.
 

June 12, 2018
A first of its kind treatment vaccine has moved into a phase I clinical trial for patients with non-small cell lung cancer (NSCLC), under a collaboration agreement between Cancer Research UK and Asterias Biotherapeutics Inc.

A first of its kind treatment vaccine has moved into a phase I clinical trial for patients with non-small cell lung cancer (NSCLC), under a collaboration agreement between Cancer Research UK and Asterias Biotherapeutics Inc.

 

April 26, 2018
Personal cancer stories focus more on younger people despite majority of all cancers in the UK being diagnosed in over 60s

Older adults are underrepresented in the media’s coverage of cancer and cancer experiences, researchers have found. This is despite over three quarters of all cancers in the UK being diagnosed in those aged over 60.

 

According to research led by the University of Glasgow and funded by Cancer Research UK, articles featuring personal cancer stories more frequently focus on younger people.

 

April 11, 2018
New centres being set up across the country mark a 'step change' in cancer care NHS England said

‘One stop shops’ aimed at speeding up cancer diagnosis are being rolled out across the country, NHS England has announced (3 April).

 

Rapid diagnostic and assessment centres are being piloted in ten areas as part of NHS England’s drive to catch cancer early and help save lives.

 

March 26, 2018
Positive opinion for ABP 980 is supported by Phase III data in patients with HER2-postive early breast cancer

Amgen and Allergan have announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorisation of ABP 980, a biosimilar to Herceptin® (trastuzumab).

 

January 19, 2018
Marketing authorisation based on global development program showing MVASI is highly similar to Avastin® (bevacizumab)

Amgen and Allergan plc have that the European Commission (EC) has granted marketing authorisation for MVASI® (biosimilar bevacizumab).

 

November 27, 2017
Survey highlights need for improved education and standardised referral pathways for oncofertility

Results of a new survey highlight the need for improved education and standardised guidance for oncologists initiating cancer treatment in women who may want to safeguard their fertility.1

 

November 10, 2017
ABP 215 is being developed as a biosimilar to bevacizumab

Amgen and Allergan have announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the Marketing Authorisation of ABP 215, a biosimilar to Avastin® (bevacizumab).

 

January 18, 2017
In their position paper published in ESMO Open, the European Society for Medical Oncology outlines the potential benefit of biosimilars to patients and healthcare systems.

October 29, 2010
The strain of chemotherapy can cause the body to activate stress defences which then shield cancer cells, a study has discovered

teaser

October 27, 2010
Combining chemotherapy drugs with radiotherapy has been shown to reduce the chance of bladder cancer returning by a third

teaser

October 22, 2010
Research has revealed that a daily low dose of aspirin can reduce the chances of suffering or dying from bowel cancer

teaser

October 12, 2010
A study has revealed that a drug used to treat bowel, breast and lung cancer could help prolong the lives of women suffering from ovarian cancer

teaser

October 12, 2010
Afatinib (BIBW 2992*) triples progression free survival in phase III study in lung cancer patients

teaser

October 8, 2010
In its final appraisal determination (FAD) the National Institute for Health and Clinical Excellence (NICE) has upheld its draft appraisal to not recommend Mepact

teaser

October 6, 2010
A pharmacy group has warned that the

teaser

October 5, 2010
Community pharmacists have been urged to help increase awareness of lung cancer by the Royal Pharmaceutical Society

teaser

March 3, 2010
The marketing application for a cancer drug has been rejected in the US due to insufficient testing data

teaser

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine